Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | PGD | P52209 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422500 | 0.86 | PDE4A (0.48) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL7076428 | 0.85 | PDE4A (0.32) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL7764499 | 0.84 | PDE4A (0.52) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL30924493 | 0.83 | PGD (0.42) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL19514770 | 0.81 | LMNA (0.42) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL27772430 | 0.81 | LMNA (0.42) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL9456987 | 0.81 | LMNA (0.42) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL7695502 | 0.81 | LMNA (0.42) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL17555601 | 0.81 | LMNA (0.42) | PDE4AUSP2SLCO1B1PGDLMNA | |
| SCHEMBL177758 | 0.77 | MPI (0.46) | PDE4ALMNAL3MBTL1TDP1MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004235-B1 | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL-DERMATOLOGICAL USE | PHARMALAND S A (SM) | 2010-03-24 | — | — | EP | disclosed |
| US-20090098226-A1 | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL-DERMATOLOGICAL USE | SCHARPER S.P.A. (IT) | 2009-04-16 | — | — | US | disclosed |
| EP-2004235-A2 | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL-DERMATOLOGICAL USE | Scharper S.p.A. (IT) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007105071-A2 | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL-DERMATOLOGICAL USE | SCHARPER S.P.A. (IT) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098226-A1 | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL-DERMATOLOGICAL USE | CUTA, DSG1, PHOSPHO1 | PDE4A 3351/4885USP2 2518/4885SLCO1B1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.